title: [Helicobacter pylori -- 2010].
abstract: Helicobacter pylori, discovered 27 years ago, has remained the most prevalent infectious agent in the world. In the author's hypothesis, the increase of peptic ulcer prevalence in the 19-20th century could be attributable to the extended worldwide use of gastric tubes for secretory testing which led to the iatrogenic transmission of pathogenic strains. Helicobacter pylori outer membrane proteins (OMP), and duodenal ulcer promoting (dupA) proteins were identified as novel virulence factors, leading to the production of pro-inflammatory cytokines, which could be future targets of therapy. There is no ideal first-line eradication of the infection and according to expert's opinion, the efficiency of these regimens has fallen gradually in recent years to unacceptably low levels; however, in the author's opinion this is a multifactorial phenomenon which can not be generalized. As alternative drugs, the efficiency of levofloxacin, furazolidone and rifabutin has been proven by meta-analyses. Sequential and bismuth-free quadruple therapies, although highly efficient, are not yet used on a large scale. The recurrence of the infection is 2.27%/year in developed and of 13.0%/year in developing countries. Spontaneous eradication occurred in 8-20% of the children and 5-11% of adults. The prevalence of clarithromycin resistance is increasing worldwide. In Hungary, it has reached 10.9% in county cities, according to a national survey. In a district of Budapest called Ferencváros, the prevalence between 2005 and 2009 was 16-22%, with no increasing trend. The development of enzymatic inhibitors (urease, carbonic anhydrase and gamma-glutamyl transpeptidase), modified antibiotics and efflux pump inhibitors seem promising ways because these compounds do not lead to resistance; however, none have yet been used in humans.
authors.affiliation: Ferencvárosi Egészségügyi Szolgáltató Kiemelkedően Közhasznú Non-Profit Kft. Gasztroenterológiai szakrendelés Budapest Mester utca 45. 1095. drbgym@gmail.com
authors.forename: György Miklós
authors.initials: GM
authors.lastname: Buzás
mesh_terms: D000367:Age Factors; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D000942:Antigens, Bacterial / Q000097:blood / Q000378:metabolism; D001425:Bacterial Outer Membrane Proteins / Q000378:metabolism; D001426:Bacterial Proteins / Q000097:blood / Q000378:metabolism; D002256:Carbonic Anhydrases / Q000187:drug effects; D017291:Clarithromycin / Q000627:therapeutic use; D018450:Disease Progression; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000382:microbiology; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000453:epidemiology* / Q000266:history / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects / Q000276:immunology / Q000302:isolation & purification / Q000472:pathogenicity; D049672:History, 19th Century; D049673:History, 20th Century; D006801:Humans; D010437:Peptic Ulcer / Q000266:history / Q000382:microbiology*; D015995:Prevalence; D012008:Recurrence; D012075:Remission, Spontaneous; D014510:Urease / Q000037:antagonists & inhibitors
chemical_list: D000897:Anti-Ulcer Agents; D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; D001426:Bacterial Proteins; D004791:Enzyme Inhibitors; C074689:VacA protein, Helicobacter pylori; C080866:cagA protein, Helicobacter pylori; D014510:Urease; D002256:Carbonic Anhydrases; D017291:Clarithromycin